Deepak A. Kapoor, MD, LUGPA president, chairman and CEO of Integrated Medical Professionals, PLLC, believes that regardless of what the guidelines says, urologists are united in their defense of a patient’s right to access PSA testing, if it is clinically appropriate.
Over the past two decades, since the advent of broad-base cancer screening, the prostate cancer specific death rate has decreased by nearly 40%, Kapoor says. Additionally, the 10-year survival rate has increased from 53% to over 97%. Simultaneously, adds Kapoor, the incidence of prostate cancer has remained unchanged, indicating that screening did not just detect more cancer but that it also detected cancer earlier, which saved lives.
Watch Dr. Kapoor’s interview with OncLiveTV below and read more at OncLive.com.